Skip to content

Study · Randomized controlled trial · 2024

6 results

Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial.

Vernstrøm L, Gullaksen S, Sørensen SS, Funck KL, Laugesen E, Poulsen PL

Diabetes, obesity & metabolism19 Jan 2024Cited by 22 (Europe PMC)

PMID38240066 (opens in a new tab)DOI10.1111/dom.15464 (opens in a new tab)PepBankPUB-38240066
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, carotid-femoral pulse wave velocity did not change significantly with semaglutide compared with placebo over 32 weeks.

    In plain wordsIn adults with type 2 diabetes, semaglutide did not change arterial stiffness compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeCarotid-femoral pulse wave velocity (arterial stiffness)
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated · 32 weeksAs given in this study (human).

    Source sentences

    Summary
    The carotid-femoral pulse wave velocity did not change significantly in any of the groups compared with placebo.
    2 context sentences
    Summary · context
    Empagliflozin, semaglutide, or their combination did not reduce arterial stiffness.
    Summary · context
    In total, 120 patients with type 2 diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, semaglutide, empagliflozin, and their combination.

Studies that did not test the peptide alone5

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 02HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the combination of empagliflozin and semaglutide did not significantly change carotid-femoral pulse wave velocity compared with placebo over 32 weeks.

    In plain wordsIn adults with type 2 diabetes, empagliflozin plus semaglutide did not change arterial stiffness compared with placebo.

    Peptide
    Semaglutide
    Outcome
    No significant changeCarotid-femoral pulse wave velocity with empagliflozin plus semaglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    The carotid-femoral pulse wave velocity did not change significantly in any of the groups compared with placebo.
    2 context sentences
    Summary · context
    Empagliflozin, semaglutide, or their combination did not reduce arterial stiffness.
    Summary · context
    In total, 120 patients with type 2 diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, semaglutide, empagliflozin, and their combination.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 03HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, combined empagliflozin and semaglutide reduced 24-h systolic blood pressure by 10 mmHg, more than placebo and more than either drug alone.

    In plain wordsIn adults with type 2 diabetes, empagliflozin plus semaglutide lowered 24-hour systolic blood pressure more than placebo or either drug alone.

    Peptide
    Semaglutide
    Outcome
    Decrease24-h systolic blood pressure with empagliflozin plus semaglutide
    Study

    n: not reported in source

    Comparator
    Placebo and monotherapy (pooled)
    Analysis
    Secondary
    Outcome group
    Blood pressure · Cardiovascular

    Measurements

    24-h systolic BP change
    10 mmHg
    combination group

    Source sentences

    Summary
    Twenty-four-hour systolic BP was reduced by 10 mmHg (95% CI 6-14), p < .001 in the combination group, significantly superior to both placebo and monotherapy (p < .05).
    1 context sentence
    Summary · context
    In total, 120 patients with type 2 diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, semaglutide, empagliflozin, and their combination.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 04HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, combined empagliflozin and semaglutide increased glycaemic time in range from 72% at baseline to 91% at week 32.

    In plain wordsIn adults with type 2 diabetes, empagliflozin plus semaglutide raised the share of time with glucose in range from 72% to 91%.

    Peptide
    Semaglutide
    Outcome
    IncreaseGlycaemic time in range with empagliflozin plus semaglutide
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    Time in range
    72%
    baseline
    Time in range
    91%
    week 32

    Source sentences

    Summary
    Combination treatment increased glycaemic time in range from 72% at baseline to 91% at week 32, p < .001, without increasing time below range.
    1 context sentence
    Summary · context
    In total, 120 patients with type 2 diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, semaglutide, empagliflozin, and their combination.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  4. 05HumanNot a test of Semaglutide aloneRandomized controlled trialSafety outcome

    In adults with type 2 diabetes, combined empagliflozin and semaglutide did not increase time below the glucose range.

    In plain wordsIn adults with type 2 diabetes, empagliflozin plus semaglutide did not increase time with low glucose.

    Peptide
    Semaglutide
    Outcome
    No significant changeTime below glucose range with empagliflozin plus semaglutide
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    without increasing time below range.
    1 context sentence
    Summary · context
    In total, 120 patients with type 2 diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, semaglutide, empagliflozin, and their combination.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  5. 06HumanNot a test of Semaglutide aloneRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, combined empagliflozin and semaglutide decreased the urinary albumin to creatinine ratio by 36% compared with placebo.

    In plain wordsIn adults with type 2 diabetes, empagliflozin plus semaglutide lowered urine albumin to creatinine ratio more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseUrinary albumin to creatinine ratio with empagliflozin plus semaglutide
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Secondary
    Outcome group
    Kidney function · Kidney and urinary

    Measurements

    UACR decrease
    36%
    combination vs placebo

    Source sentences

    Summary
    The urinary albumin to creatinine ratio decreased by 36% (95% CI 4-57), p = .03 in the combination group compared with placebo.
    1 context sentence
    Summary · context
    In total, 120 patients with type 2 diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, semaglutide, empagliflozin, and their combination.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.